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RRhinotillexis: A Possible
Heuristic to Reduce Inappropriate
Noninvasive Cardiac Imaging?
Hachamovitch et al. (1) presented findings from the prospectively
acquired SPARC (Study of Myocardial Perfusion and Coronary
Anatomy Imaging Roles in Coronary Artery Disease [CAD])
registry. Enrolled patients had intermediate to high likelihood of
CAD and were referred for “clinically indicated” noninvasive
cardiac imaging tests. The authors reported data on medication
changes as well as referrals for both cardiac catheterization and
revascularization at 90 days, based on results of these imaging tests.
One of the main findings was a concerning lack of medical therapy
optimization and cardiac catheterization referrals in those found to
have moderately to severely abnormal findings on initial imaging
(1). This is particularly concerning because 80% of the SPARC
registry patients had “anginal symptoms” at enrollment (1). One
presumes that the majority of these had stable angina; however, it
would be helpful if the authors could report what proportion had
unstable angina (recognizing that chest pain at rest was one study
exclusion criterion [2]).
The authors reported that 24% of patients with moderately to
severely abnormal findings were not receiving aspirin, 44% were
not receiving beta-blockade, and 23% were not receiving lipid-
lowering agents at 90 days. These suboptimal results were accen-
tuated by the use of patient self-report for medication changes
(frequently overestimated [3]) and the relatively short duration of
follow-up. A number of studies have demonstrated a decline in
ongoing medication compliance months after initial imaging
results induced medication changes (4). We previously published
similar results from a large matched-cohort study evaluating the
impact of coronary computed tomography angiography (CCTA)
findings on secondary test referrals and medication use in a
lower-risk cohort (3). We found that our 90-day adjusted odds
ratios for aspirin use (6.8) and statin use (4.6) in those with
abnormal CCTA (compared with controls) were much reduced at
18 months (4.2 for aspirin and 3.3 for statins). The original
SPARC protocol also included assessment of medication use at 1
and 2 years’ follow-up (2). We wonder whether the authors can
report their medication use findings over longer follow-up.
Similarly, half of those with moderate to severe abnormalities
were not referred for cardiac catheterization. The authors posited
that the low number of catheterization referrals may have been due
to equipoise. Certainly, the widely disseminated results of the
COURAGE (Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) trial support this theory (5). That
aid, the SPARC study definition of a moderate to severe abnor-
ality on CCTA was “50% left main stenosis, 70% stenosis in
he proximal left anterior descending artery, or 3-vessel CAD with
70% stenosis.” With such high-grade CAD, it is disconcertingthat 40% of these symptomatic CCTA patients did not undergo
catheterization.
Thus, many patients are presumably being sent for wasteful
imaging tests because even markedly abnormal results do not
influence the referring physicians’ management. This brings to
mind a common medical heuristic from our hospital regarding
public displays of rhinotillexis, “you better have a plan if you find
something in there.” Physicians would do well to remember this
when ordering such cardiac imaging tests.
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CTCA Versus MPI 
Anatomical Versus Functional
Hachamovitch et al. (1) reported increased referral rates for
coronary angiography in patients with an intermediate to high
probability of coronary artery disease following coronary computed
tomography angiography (CCTA) as compared with myocardial
perfusion imaging (MPI). Several hypotheses for this discrepancy
were offered. Although these may well be correct, the fact remains
RR
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July 31, 2012:432–3that these 2 tests are fundamentally different and provide different
information; we suggest that it is this difference that drives the
increased referral rate seen for CCTA.
CCTA is an anatomic test that provides information about the
presence, location, and severity of a stenosis but does not offer the
ability to determine whether the stenosis is responsible for isch-
emia. MPI is a functional test offering little in anatomic data but
providing clarity on the presence or absence of ischemia.
A patient with multiple risk factors presenting with angina (as
in 75% of the study population) who has a reported 65% left
anterior descending artery stenosis on CCTA would be deemed to
have a mild abnormality in the study. However, once these
anatomic data are obtained, we feel it would be difficult for the
clinician to ignore this finding, and hence further investigations
(likely angiography with a view to possible stenting) would be
requested. However, such a stenosis may not be flow limiting and
responsible for ischemia and may not be demonstrated on MPI. If
it is demonstrated that the ischemic burden may be low, further
tests may be unnecessary. We believe it is this that accounts for the
increased referral rates seen.
Before requesting a test, clinicians must decide whether they are
seeking anatomic or functional data.
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Reply
We thank Dr. McEvoy and colleagues for their comments on our
paper (1). The patients included in this report of the SPARC
(Study of Myocardial Perfusion and Coronary Anatomy Imaging
Roles in Coronary Artery Disease [CAD]) registry did not have a
prior history of CAD and were required to have intermediate to
high pretest likelihood of CAD. The SPARC exclusion criteria
mandated that patients be clinically stable. Thus, patients with
unstable angina (resting chest pain) within 48 h of testing were
excluded.
We agree with the comments that the use of patient self-
reported medication changes and the relatively short-term
follow-up likely overestimated the suboptimal use of medical
therapy, especially given the known fact that compliance withmedical therapy is reduced over time as demonstrated by Dr.
McEvoy and colleagues and others. We also agree that the 1-year
follow-up data from SPARC will add potentially important
information on this question in symptomatic patients.
We were also surprised about the relatively low referral rate to
catheterization, especially among those with high-grade CAD on
computed tomography angiography. It is important to note that
these relatively low referral rates to catheterization after stress
cardiac single-photon emission computed tomography were first
reported more than 15 years ago and confirmed by multiple
studies.
Our findings indicated that an additional facet of excess testing
includes the failure of referring physicians to act on the results of
testing in “appropriate” patients. Although patient selection, image
acquisition, image interpretation, and results communication have
been identified as the key components of imaging quality (1),
referring physicians’ action, implicated in this process via pretest
patient selection and posttest patient management, must also be
considered a necessary component of the definition of imaging
quality. We can no longer assume that communication of results
ensures optimal patient care. Finally, we agree with Dr. McEvoy
and colleagues that we were all taught that one should not order a
test without a clear plan as to how the results will impact
subsequent treatment. Perhaps this mantra can be revisited.
We thank Drs. Cookson and Sahebjalal for their comments and
agree that before ordering a test, physicians must decide what type
of information they are seeking. In the authors’ example, they
stated that it would be difficult for a referring physician to “ignore”
a 65% left anterior descending artery stenosis on coronary com-
puted tomography angiography and he would need to investigate
further. We agree that the physiological significance of this lesion
would need to be investigated, usually with a stress test. However,
the use of stress myocardial perfusion imaging post–computed
tomography angiography in the SPARC registry was actually
relatively low.
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